Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBIT (2016 - 2025)

Historic EBIT for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$628145.0.

  • China Pharma Holdings' EBIT rose 4212.02% to -$628145.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 2932.72%. This contributed to the annual value of -$4.6 million for FY2024, which is 6675.75% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' EBIT is -$628145.0, which was up 4212.02% from -$652120.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year EBIT high stood at -$397479.0 for Q1 2023, and its period low was -$1.4 million during Q2 2024.
  • For the 5-year period, China Pharma Holdings' EBIT averaged around -$831002.9, with its median value being -$758618.0 (2025).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 110413.15% in 2021, then soared by 5640.33% in 2023.
  • Over the past 5 years, China Pharma Holdings' EBIT (Quarter) stood at -$648690.0 in 2021, then plummeted by 80.21% to -$1.2 million in 2022, then decreased by 1.32% to -$1.2 million in 2023, then fell by 0.97% to -$1.2 million in 2024, then surged by 47.48% to -$628145.0 in 2025.
  • Its EBIT stands at -$628145.0 for Q3 2025, versus -$652120.0 for Q2 2025 and -$758618.0 for Q1 2025.